Topical Application of AS101 for the Treatment of Atopic Dermatitis

Inclusion Criteria:

• Diagnosed Atopic Dermatitis for at least 6 months prior to enrollment.
• Diseased Body surface area (BSA) ≤ 20%.
• Male and Female ≥ 18.
• Adequate general health.
• Signed Informed consent form by the patient or his/her legal guardian.
• Patient must be able and willing to comply with all protocol requirements.

Exclusion Criteria:

• Patient who is unable to provide fully informed consent.
• Pregnant of breast-feeding females.
• Concomitant dermatologic or medical condition(s) which may interfere with the patient's response evaluation.
• Evidence of an infection in the targeted zones.
• Known sensitivity to any of the drug component.
• Immunocompromised patients.

• Concomitant medications such as:

  • Topical corticosteroid within 2 weeks prior to Day 1 visit;
  • Systemic steroids and immunosuppressants within 1 month prior to Day 1 visit; *Systemic anti-histamines and antibiotics within 2 weeks prior to Day 1 visit; *Phototherapy within 4 weeks prior to Day 1 visit;
  • Anticipated exaggerated exposure to sunlight during the whole treatment period and 4 weeks prior to Day 1 visit.